Free Trial

RxSight (RXST) Competitors

RxSight logo
$8.61 +0.18 (+2.14%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$8.72 +0.11 (+1.22%)
As of 10/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RXST vs. BLFS, KMTS, PLSE, TNDM, MDXG, INMD, IRMD, BBNX, EMBC, and AXGN

Should you be buying RxSight stock or one of its competitors? The main competitors of RxSight include BioLife Solutions (BLFS), Kestra Medical Technologies (KMTS), Pulse Biosciences (PLSE), Tandem Diabetes Care (TNDM), MiMedx Group (MDXG), InMode (INMD), iRadimed (IRMD), Beta Bionics (BBNX), Embecta (EMBC), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry.

RxSight vs. Its Competitors

RxSight (NASDAQ:RXST) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

78.8% of RxSight shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 9.6% of RxSight shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

RxSight presently has a consensus price target of $10.00, indicating a potential upside of 16.14%. BioLife Solutions has a consensus price target of $31.29, indicating a potential upside of 8.67%. Given RxSight's higher possible upside, research analysts clearly believe RxSight is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight
3 Sell rating(s)
9 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.85
BioLife Solutions
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

BioLife Solutions has a net margin of -5.39% compared to RxSight's net margin of -21.93%. BioLife Solutions' return on equity of 0.16% beat RxSight's return on equity.

Company Net Margins Return on Equity Return on Assets
RxSight-21.93% -11.56% -10.31%
BioLife Solutions -5.39%0.16%0.14%

BioLife Solutions has lower revenue, but higher earnings than RxSight. BioLife Solutions is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RxSight$139.93M2.52-$27.45M-$0.80-10.76
BioLife Solutions$82.25M16.77-$20.18M-$0.12-239.92

In the previous week, BioLife Solutions had 11 more articles in the media than RxSight. MarketBeat recorded 14 mentions for BioLife Solutions and 3 mentions for RxSight. RxSight's average media sentiment score of 0.98 beat BioLife Solutions' score of 0.95 indicating that RxSight is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RxSight
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioLife Solutions
7 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

RxSight has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500.

Summary

BioLife Solutions beats RxSight on 11 of the 16 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXST vs. The Competition

MetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$344.92M$7.83B$6.23B$10.66B
Dividend YieldN/A1.12%5.71%4.82%
P/E Ratio-10.7627.3330.2030.21
Price / Sales2.529.76590.34132.63
Price / CashN/A22.8437.0161.44
Price / Book1.235.2612.046.60
Net Income-$27.45M$178.09M$3.32B$276.82M
7 Day Performance4.49%1.32%1.89%2.58%
1 Month Performance-4.97%3.23%7.68%3.76%
1 Year Performance-82.91%4.47%56.01%33.84%

RxSight Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXST
RxSight
2.1935 of 5 stars
$8.61
+2.1%
$10.00
+16.1%
-82.6%$344.92M$139.93M-10.76220
BLFS
BioLife Solutions
2.1047 of 5 stars
$27.86
+2.0%
$31.29
+12.3%
+33.2%$1.31B$82.25M-232.15440News Coverage
Analyst Forecast
Insider Trade
KMTS
Kestra Medical Technologies
0.7433 of 5 stars
$26.85
+9.1%
$27.33
+1.8%
N/A$1.27B$66.40M0.00300News Coverage
PLSE
Pulse Biosciences
3.7724 of 5 stars
$18.21
+3.7%
$22.00
+20.8%
+0.9%$1.18B$700K-17.34140Positive News
Upcoming Earnings
TNDM
Tandem Diabetes Care
4.222 of 5 stars
$15.54
+5.1%
$22.19
+42.8%
-52.9%$999.35M$1.00B-5.032,650Analyst Forecast
MDXG
MiMedx Group
3.2208 of 5 stars
$6.75
+0.9%
$12.00
+77.8%
+18.4%$989.85M$348.88M32.14870News Coverage
Positive News
Upcoming Earnings
Analyst Downgrade
INMD
InMode
3.2983 of 5 stars
$16.01
+4.6%
$16.85
+5.2%
-13.5%$967.73M$394.82M6.48480Positive News
IRMD
iRadimed
4.5756 of 5 stars
$74.69
+1.7%
$72.00
-3.6%
+55.4%$933.67M$73.24M46.10110News Coverage
Upcoming Earnings
Insider Trade
BBNX
Beta Bionics
2.6783 of 5 stars
$20.24
+1.1%
$24.44
+20.8%
N/A$870.27M$65.12M0.00294Analyst Forecast
Short Interest ↑
Gap Up
EMBC
Embecta
4.7291 of 5 stars
$14.10
+4.0%
$19.00
+34.8%
+2.0%$793.06M$1.10B9.862,100Positive News
Analyst Forecast
AXGN
AxoGen
3.5516 of 5 stars
$16.97
+2.3%
$25.75
+51.7%
+36.5%$763.35M$187.34M-169.68450Upcoming Earnings
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:RXST) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners